Abstract
Light-chain (AL) amyloidosis is a malignant disease caused by a small monoclonal population of plasma cells in the bone marrow. This cell population produces monoclonal immunoglobulin light chains (FLC) that aggregate into amyloid fibrils and cause organ failure due to tissue deposition. In more than half of the cases there is cardiac involvement, by far the most relevant factor for poor prognosis [1]. Historically, median survival for cardiac AL amyloidosis (CA) is less than one year [1]. Two thirds of the CA patients die of cardiac causes and half of them die suddenly [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
